Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a

Insulet Corporation 10-K filed Feb 18, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Item 1A, Risk Factors, against the 10-K filed Feb 21, 2025: 10 added · 47 removed · 75 modified; 12 moved without change

132 more changes in this Item, word by word, in Powerpack.

Powerpack